StreetAlpha.app
Home › Stocks › PTN

Palatin Technologies Inc (PTN)

$5.37
▼ −13.53%
LAST CLOSE · NOV 17

Palatin is a New Jersey biopharmaceutical company developing peptide and small molecule medicines that target melanocortin receptors. It last closed at $5.37 on Nov 17, down 13.53% on the day.

AI Auto Pilots
Is PTN in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$4.7M
−46.9% vs a year ago
Net income
−$18.1M
−385.4% margin
EPS (diluted)
−$8.51
Operating margin
−392.2%
−$18.4M operating income
Valuation
Market cap
$9.6M
1.8M shares
P/E
–
No P/E while losing money
Price to sales
2.0
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$3.7M
At Sep 30
Shareholder equity
$2.0M
Shares outstanding
1.8M
At Nov 13
Fiscal year endsJune
ExchangeNasdaq
Financials history
FY2022: $1.5M$1.5MFY2022FY2023: $4.9M$4.9MFY2023FY2024: $4.5M$4.5MFY2024FY2025: $0$0FY2025FY2026: $13.2M$13.2MFY2026

From PTN's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 16). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated PTN in the past 90 days, not enough for a consensus
Average 12-month target
$12.00
▲ 123.5% upside

Based on 1 analyst who set a price target on PTN in the past 90 days. The average target is $12.00, with a high of $12.00 and a low of $12.00, compared with the last close of $5.37.

Low $12.00Avg $12.00High $12.00
Blue marker: last close $5.37
Highest target$12.00
Average target$12.00
Lowest target$12.00
Latest rating changes
HC Wainwright & Co.Initiated
Nov 6Buy$17 → $12
HC Wainwright & Co.Reiterated
Sep 25Buy$17
DateFirmActionRatingPrice target
Nov 6HC Wainwright & Co.InitiatedBuy$17 → $12
Sep 25HC Wainwright & Co.ReiteratedBuy$17
Loading…

Technical Analysis

PTN · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 6% below its 20 day and 47% below its 50 day average. It is 150% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 37), near oversold. The nearest support is the Pivot S1 at $5.00, and the nearest resistance the Pivot at $5.63.

Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityNormal, 13.2%/day
Key levels
$31.0052 week high+477.3%
$13.42200 day average+149.9%
$8.75100 day average+62.9%
$7.9250 day average+47.5%
$7.33Swing high (Nov 9)+36.5%
$6.00Pivot R1+11.7%
$5.6920 day average+6.0%
$5.63Pivot+4.8%
$5.37Last close
$5.00Pivot S1−6.9%
$4.76Swing low (Nov 5)−11.4%
$4.5152 week low−16.0%
Indicators
RSI (14)37.20Weak, oversold below 30Neutral
MACD-0.37Above its signal lineBullish
Stochastic48.5Middle of its rangeNeutral
ADX (14)24.2Weak trend
Williams %R-75.7Oversold below −80, overbought above −20Neutral
CCI (20)-6.8Oversold below −100, overbought above 100Neutral
Rate of change+2.9%Change over 10 sessionsBullish
ATR (14)$0.71Typical daily range, 13.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for PTN

What happened before

See how PTN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow PTN usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How PTN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in PTN in the last 90 days.

Loading…

See today’s whale options flow across the market →

PTN Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ●10 buying vs 10 selling
  • ▲Held by funds +9.1 pts
  • ▲Funds holding +5
  • ●No superinvestor moves
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding3025+20.0%
In funds' top 1000–
Held by funds47.6%38.5%+9.1 pts
New / increased8 / 25 / 7−16.7%
Reduced / sold out7 / 36 / 5−9.1%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See PTN institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PTN is in one of them and how their past PTN trades turned out.

PTN in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered PTN in an article yet. Here's the latest on the wider market.

About Palatin Technologies

Palatin is a biopharmaceutical company based in Cranbury, New Jersey. It develops drug candidates that act on the melanocortin receptor system, a group of receptors involved in inflammation, immune response, appetite and metabolism. Its main focus is treatments for obesity and rare diseases tied to this pathway, with other candidates aimed at eye, gut and immune conditions. The company generally works with pharmaceutical partners to license and commercialize its products.

Headquarters
Cranbury, NJ